Patient-derived gastric cancer organoids that retain key histological and molecular features of human gastric tumors, supporting studies of tumor biology, drug response, and biomarker research.
- Overview
- Details
- Advantages
- FAQs
Overview
Gastric cancer is a heterogeneous malignancy and remains a major cause of cancer-related mortality worldwide. The majority of cases are gastric adenocarcinomas, which are broadly classified into intestinal and diffuse types based on histopathology and tumor architecture. Diffuse-type gastric cancer is often associated with poor differentiation and infiltrative growth patterns.
At the molecular level, gastric cancer is characterized by diverse genetic and epigenetic alterations, including mutations in TP53, CDH1, KRAS, ARID1A, PIK3CA, and amplification of ERBB2 (HER2). Epstein-Barr virus (EBV)-associated and microsatellite instability (MSI) subtypes represent additional clinically relevant molecular categories.
Conventional 2D cell lines do not fully capture the structural organization or interpatient heterogeneity of gastric tumors. Patient-derived organoid systems provide a more representative in vitro model that preserves key tumor features and supports translational research applications.
What Pathological Features Do Gastric Cancer Organoids Recapitulate?
- Histological characteristics of intestinal-type and diffuse-type gastric adenocarcinoma
- Genetic alterations including TP53, CDH1, KRAS, ARID1A, and PIK3CA mutations
- HER2 (ERBB2) amplification status relevant to targeted therapy studies
- MSI and EBV-associated molecular subtypes
- Signet ring cell–like features in diffuse-type models
- Gastric epithelial lineage marker expression such as MUC1, MUC5AC, and EPCAM
- Tumor heterogeneity reflecting patient-specific disease profiles
- Differential sensitivity to chemotherapy and targeted agents
These characteristics make gastric cancer organoids suitable for studying disease mechanisms and evaluating therapeutic strategies in a patient-relevant context.
Fig. 1. Establishment of Gastric Cancer Organoids (Zu M, Hao X, et al., 2023).
Our Gastric Cancer Organoids
Our gastric cancer organoids are derived from primary tumor tissues and maintained under defined conditions to preserve disease-relevant molecular and histological features.
Disease-Relevant Features
- Patient-derived tumor models reflecting intestinal and diffuse gastric cancer subtypes
- Molecular heterogeneity including key oncogenic and tumor suppressor alterations
- Preservation of tumor architecture consistent with primary gastric lesions
- Clinically relevant biomarker expression including HER2 and MSI-related features
- Cryopreserved format for consistent experimental use
Characterization & Validation
Each gastric cancer organoid line is characterized to ensure identity, stability, and disease relevance.
- Genetic profiling: Detection of mutations in TP53, CDH1, KRAS, ARID1A, and PIK3CA
- Biomarker analysis: Assessment of HER2, MUC1, MUC5AC, EPCAM, and other gastric markers
- 3D morphology assessment: Evaluation of glandular or diffuse growth patterns
- Disease phenotype characterization: Analysis of proliferation and drug response behavior
- Quality control: Post-thaw viability ≥85%, identity confirmation, low batch variability, mycoplasma-free status
Applications
These organoids support a range of gastric cancer research applications:
- Disease Mechanism Studies: Investigation of gastric tumor initiation, progression, and subtype biology.
- Drug Screening: Evaluation of chemotherapy, HER2-targeted agents, and combination therapies.
- Precision Oncology: Assessment of patient-specific therapeutic responses and biomarker-driven strategies.
- Resistance Mechanism Research: Study of acquired and intrinsic resistance to therapy.
- Biomarker Discovery: Identification of predictive and prognostic markers.
Why Choose Our Gastric Cancer Organoids
- Patient-derived models that reflect gastric cancer heterogeneity
- Subtype-relevant representation of intestinal and diffuse disease
- Ready-to-use format for streamlined experimental workflows
- Consistent quality supported by standardized validation procedures
- Compatible with screening and translational research applications
FAQs
Q: What gastric cancer subtypes are represented?
The models may include intestinal-type and diffuse-type gastric adenocarcinoma, depending on the donor source.
Q: Is HER2 status available?
HER2 (ERBB2) amplification status can be characterized in applicable organoid lines for targeted therapy studies.
Q: What assays are supported?
Applications include drug response assays, imaging, immunostaining, gene expression analysis, and genomic profiling.
Q: Can customized models be generated?
Yes. Customized gastric cancer organoid models can be developed based on specific research requirements.
Accelerate gastric cancer research with physiologically relevant, ready-to-use human tumor organoids.
Contact us today to request detailed characterization data, pricing information, or customized gastric cancer organoid solutions tailored to your research needs.
Online Inquiry